ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular disease"

  • Abstract Number: 440 • 2013 ACR/ARHP Annual Meeting

    Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor

    C. Charles-Schoeman1, P Wicker2, M. A. Gonzalez-Gay3, S. P. Wood4, M.G. Boy4, J. Geier5, D. Gruben4, K. Soma4 and R. Riese4, 1Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2PW Consulting LLC, Mystic, CT, 3Reumatologia, Hospital Marques De Valdecilla, Santander, Spain, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, New York, NY

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we evaluated the cardiovascular (CV) event rates and…
  • Abstract Number: 334 • 2013 ACR/ARHP Annual Meeting

    The Joint Effect Of Carotid Ultrasound and Preventive Cardiology Referral On Cardiovascular Risk Factor Modification in Psoriatic Arthritis Patients

    Michael Lucke1, Soo Hyun Kim2 and M. Elaine Husni3, 1Rheumatology, Cleveland Clinic, Cleveland, OH, 2Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 3Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Cardiovascular disease risk is elevated in psoriatic arthritis (PsA) compared to the general population. Prior studies have demonstrated suboptimal evaluation and control of modifiable…
  • Abstract Number: 2760 • 2013 ACR/ARHP Annual Meeting

    Incidence and Severity Of Myocardial Infarction In Subjects Receiving Anti Tumour Necrosis Factor Drugs For Rheumatoid Arthritis: Results From Linking the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project

    Audrey SL Low1, Kimme L. Hyrich2, Mark Lunt3, Louise K. Mercer3, Christopher Gale4,5, Kath Watson6, British Society for Rheumatology Biologics Registers (BSRBR) Control Centre Consortium1, William G. Dixon7, Deborah P. Symmons3,8 and On behalf of the BSRBR9, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Division of Epidemiology, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United Kingdom, 5Department of Cardiology,York Teaching Hospital NHS Foundation Trust, York, United Kingdom, 6Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 7The University of Manchester, Manchester, United Kingdom, 8Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 9British Society for Rheumatology, London, United Kingdom

    Background/Purpose: Subjects with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared to subjects without RA, with the increased risk potentially driven…
  • Abstract Number: 1720 • 2013 ACR/ARHP Annual Meeting

    Risk Of Cardiovascular Disease and Use Of Xanthine Oxidase Inhibitors For Gout

    Seoyoung C. Kim1, Sebastian Schneeweiss2, Niteesh Choudhry3, Jun Liu4, Robert J. Glynn3 and Daniel H. Solomon3, 1Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Hyperuricemia and gout are associated with an increased risk of hypertension and cardiovascular disease (CVD) such as myocardial infarction (MI) and stroke. Xanthine oxidase…
  • Abstract Number: 805 • 2013 ACR/ARHP Annual Meeting

    Good Response On Tumour Necrosis Factor Inhibitors Are Associated With a Decreased Risk Of Acute Coronary Syndromes In Patients With Rheumatoid Arthritis

    Lotta Ljung1,2, Lennart T.H. Jacobsson3, Solbritt M. Rantapää-Dahlqvist4, Johan Askling5 and The ARTIS Study Group6, 1Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, 2Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 3Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 4Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 5Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 6Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Inflammatory activity, as well as traditional cardiovascular risk factors, have been suggested to underlie the increased risk of coronary disease in patients with rheumatoid…
  • Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition

    Cem Gabay1, Katie Tuckwell2, Jennifer Green2, Micki Klearman3 and Arthur Kavanaugh4, 1SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 2Roche, Welwyn Garden City, United Kingdom, 3Roche, South San Francisco, CA, 4University of California, San Diego, La Jolla, CA

    Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…
  • Abstract Number: 303 • 2013 ACR/ARHP Annual Meeting

    Risk Of Cardiovascular Events In Patients With Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A General Population-Based Cohort Study

    Alexis Ogdie1, Yiding Yu2, Kevin Haynes3, Samantha Maliha4, Thorvardur Love5,6, Andrea Troxel7, Sean Hennessy8, David Margolis9, Stephen Kimmel10, Nehal N. Mehta11, Hyon Choi12,13 and Joel Gelfand14, 1Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, 2Medicine, Brigham and Women's Hospital, Boston, MA, 3Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 4University of Pennsylvania, Philadelphia, PA, 5Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 6Landspitali University Hospital, Reykjavik, Iceland, 7Biostatistics and Epidemiology, University of Pennsylvania., Philadelphia, PA, 8Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, 9Dermatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, 10Cardiology and Epidemiology, University of Pennsylvania, Philadelphia, PA, 11National Heart Lung Blood Institute, Cardiovascular and Pulmonary Division, NHLBI, National Institutes of Health, Bethesda, MD, 12Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 13Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, 14Dermatology and Epidemiology, University of Pennsylvania., Philadelphia, PA

    Risk of Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A general population-based cohort studyBackground/Purpose: Psoriatic arthritis (PsA), psoriasis, and rheumatoid arthritis…
  • Abstract Number: 2766 • 2013 ACR/ARHP Annual Meeting

    Improvement In Insulin Resistance Greater With The Use Of Infliximab Following Intensive Treatment Of Early Rheumatoid Arthritis

    Lesley-Anne Bissell1, Elizabeth Hensor2, Sarah L. Mackie2, Agata Burska3, Jackie L. Nam2, Lukasz Kozera2, Helen I. Keen4, Edith Villeneuve2, Heike Eberl5, Helena Donica6, Philip G. Conaghan7, Jacqueline Andrews2, Paul Emery8 and Ann W. Morgan2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, Translational Research in Immune Mediated Inflammatory Diseases, the University of Leeds, Leeds, AL, United Kingdom, 4Leeds, Leeds, United Kingdom, 5Roche Molecular Diagnostics, Burgess Hill, United Kingdom, 6Department of Biochemical Diagnostics, Medical University of Lublin, Lublin, Poland, 7NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 8Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Insulin resistance (IR), N-terminal pro-brain natriuretic peptide (NT-proBNP) and total cholesterol/high density lipoprotein cholesterol ratio (TC/HDL-C) profiles have been proposed as surrogate measures of…
  • Abstract Number: 1672 • 2013 ACR/ARHP Annual Meeting

    Serious Cardiovascular Events Risk Factors In Giant Cell Arteritis. A Population-Based Study In The French Apogee Cohort

    Grégory Pugnet1, Laurent Sailler2, Guillaume Moulis3, Jean-Pascal Fournier4, Robert Bourrel5, Jean-Louis Montastruc6 and Maryse lapeyre-Mestre6, 1Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, 2Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, 3Clinical Pharmacology Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, 4Toulouse University, INSERM UMR 1027, Toulouse, France, 5Service Médical, Caisse Nationale de l'Assurance Maladie échelon régional, Midi-Pyrénées, Toulouse, France, 6Department of Clinical Pharmacology, Toulouse University Hospital, INSERM U1027, University of Toulouse, France, Toulouse, France

    Background/Purpose: No population-based study has assessed serious cardiovascular events (sCVE) risk factors in Giant Cell Arteritis (GCA). The aim of our study was to identify…
  • Abstract Number: 779 • 2013 ACR/ARHP Annual Meeting

    Low Cardiovascular Mortality Among Early Rheumatoid Arthritis Patients — A Nationwide Register Study 2000—2008

    Anne M. Kerola1, Tuomo Nieminen2, Lauri J. Virta3, Hannu Kautiainen4, Kari Puolakka5, Tuomas Kerola6, Timo Pohjolainen7 and Markku J. Kauppi6, 1Medical School, University of Helsinki, Helsinki, Finland, 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, 3Research Department, the Social Insurance Institution, Turku, Finland, 4Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, 5Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, 6Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 7ORTON Rehabilitation Centre, ORTON Foundation, Helsinki, Finland

    Background/Purpose: Increased cardiovascular (CV) mortality in established rheumatoid arthritis (RA) is a widely accepted threat, but in early RA or inception cohorts, growing evidence suggests…
  • Abstract Number: 421 • 2013 ACR/ARHP Annual Meeting

    Enhanced Cardiovascular Risk Factor Screening In Rheumatoid Arthritis: Does This Have a Sustained Impact?

    Mark J Ponsford1, Jennifer K. Cooney2, Bethany Anthony3, Fflur A. Huws4, Lauren Evans1, Jeanette Thom5 and Yasmeen Ahmad1, 1Betsi Cadwaladr University Health Board, Peter Maddison Research Centre, Llandudno, United Kingdom, 2School of Sport, Health and Exercise Sciences, School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, 3Health and Exercise Sciences, School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, 4Health and Exercise Sciences, Bangor University, School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, 5School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) patients face a burden of cardiovascular disease (CVD) twice that of the general population. RA patients have reduced physical fitness, a…
  • Abstract Number: 285 • 2013 ACR/ARHP Annual Meeting

    Juvenile Idiopathic Arthritis Patients Demonstrate Alterations In HDL Functionality Without Accelerated Subclinical Atherosclerosis

    Preethi Mani1, Kiyoko Uno2, Katherine Wolski3, Steven J. Spalding4, Stephen J. Nicholls5 and M. Elaine Husni6, 1Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 2Cardiovascular medicine, Cleveland Clinic Foundation, Cleveland, OH, 3Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, 4Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, 5Clinical Research Heart & Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, 6Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Previous literature supports an increase in cardiovascular (CV) morbidity and mortality in adults with inflammatory joint disease, however it is not known whether children with…
  • Abstract Number: 2726 • 2013 ACR/ARHP Annual Meeting

    A Polymorphism In The Mif Gene Is Associated With Cardiovascular Morbidity In Systemic Lupus Erythematosus – a Pilot Study

    Eric F. Morand, Kathryn Connelly and Alberta Y. Hoi, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia

    Background/Purpose: Chronic inflammation is believed to be responsible for accelerated atherosclerotic cardiovascular disease (CVD) in patients with SLE. Macrophage migration inhibitory factor (MIF) is a…
  • Abstract Number: 1674 • 2013 ACR/ARHP Annual Meeting

    Acute Coronary Syndromes In Patients With Giant Cell Arteritis:  A Population Based Retrospective Cohort Study

    P. Deepak Udayakumar1, Arun K. Chandran1, Cynthia S. Crowson2, Kenneth J. Warrington3 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose:  Acute coronary syndrome (ACS) is one of the leading causes of death in the general population. We aimed at assessing the occurrence of ACS…
  • Abstract Number: 783 • 2013 ACR/ARHP Annual Meeting

    Outcome In Patients With Rheumatoid Disease: Simple Screening Tools Predict Cardiovascular Events and Death

    Stefan Kleinert1, Margret Breunig2, Hans-Peter Tony3, Martin Feuchtenberger4, Marc Schmalzing5, Christian Kneitz6, Stefanie Lehmann7, Christiane Angermann7,8, Georg Ertl8 and Stefan Störk7, 1Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, 2Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Wuerzburg, Germany, 3Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, 4Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, 5Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, 6Internal Medicine II, Hospital Südstadt, Rostock, Germany, 7Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany, 8Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Germany

    Background/Purpose: Patients with rheumatoid disease (RD) have an increased mortality risk compared to the normal population, mainly due to cardiovascular (CV) disease. Only a proportion…
  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology